Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes: A randomized intraindividual comparison study

E. Sotiriou, Z. Apalla, F. Vrani, A. Lallas, E. Chovarda, D. Ioannides

Research output: Contribution to journalArticle

Abstract

Background: Actinic damage is responsible for the development of multiple, recurrent non-melanoma skin cancers (NMSCs), including actinic keratoses (AKs). Photodynamic therapy (PDT) and imiquimod cream (IMIQ) 5% are recommended as field-directed treatment options. Objectives: To compare efficacy and safety of methyl aminolevulinate (MAL)-PDT vs. IMIQ 5% in the prevention of new NMSCs development patients with field changes. Methods: Patients with field cancerization of the face or scalp were randomized to receive MAL-PDT on one side, and IMIQ 5% on the mirror field. The primary endpoint was the number of new lesions on the treated fields during a 12-month follow-up period. Secondary assessments included adverse events and patient preference. Results: Forty-four patients completed the study. MAL-PDT and IMIQ did not differ concerning the primary endpoint, as there was no statistically significant difference in terms of development of new NMSCs at any point of follow-up. Both treatment regimens were safe and well tolerated. Patients' preference based on the procedure, response rates and future choice favoured MAL-PDT. Conclusions: MAL-PDT and IMIQ 5% are safe and well-tolerated treatments that equally prevent development of new AKs in patients suffering from field changes. MAL-PDT treatment appears to be superior in terms of patients' preference.

Original languageEnglish
Pages (from-to)325-329
Number of pages5
JournalJournal of the European Academy of Dermatology and Venereology
Volume29
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

imiquimod
Photochemotherapy
Skin Neoplasms
Patient Preference
Actinic Keratosis
Therapeutics
Scalp
Safety

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases
  • Medicine(all)

Cite this

Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes : A randomized intraindividual comparison study. / Sotiriou, E.; Apalla, Z.; Vrani, F.; Lallas, A.; Chovarda, E.; Ioannides, D.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 29, No. 2, 01.02.2015, p. 325-329.

Research output: Contribution to journalArticle

@article{ee79fdc66fe84c66b23d120a513e3ae8,
title = "Photodynamic therapy vs. imiquimod 5{\%} cream as skin cancer preventive strategies in patients with field changes: A randomized intraindividual comparison study",
abstract = "Background: Actinic damage is responsible for the development of multiple, recurrent non-melanoma skin cancers (NMSCs), including actinic keratoses (AKs). Photodynamic therapy (PDT) and imiquimod cream (IMIQ) 5{\%} are recommended as field-directed treatment options. Objectives: To compare efficacy and safety of methyl aminolevulinate (MAL)-PDT vs. IMIQ 5{\%} in the prevention of new NMSCs development patients with field changes. Methods: Patients with field cancerization of the face or scalp were randomized to receive MAL-PDT on one side, and IMIQ 5{\%} on the mirror field. The primary endpoint was the number of new lesions on the treated fields during a 12-month follow-up period. Secondary assessments included adverse events and patient preference. Results: Forty-four patients completed the study. MAL-PDT and IMIQ did not differ concerning the primary endpoint, as there was no statistically significant difference in terms of development of new NMSCs at any point of follow-up. Both treatment regimens were safe and well tolerated. Patients' preference based on the procedure, response rates and future choice favoured MAL-PDT. Conclusions: MAL-PDT and IMIQ 5{\%} are safe and well-tolerated treatments that equally prevent development of new AKs in patients suffering from field changes. MAL-PDT treatment appears to be superior in terms of patients' preference.",
author = "E. Sotiriou and Z. Apalla and F. Vrani and A. Lallas and E. Chovarda and D. Ioannides",
year = "2015",
month = "2",
day = "1",
doi = "10.1111/jdv.12538",
language = "English",
volume = "29",
pages = "325--329",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "2",

}

TY - JOUR

T1 - Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes

T2 - A randomized intraindividual comparison study

AU - Sotiriou, E.

AU - Apalla, Z.

AU - Vrani, F.

AU - Lallas, A.

AU - Chovarda, E.

AU - Ioannides, D.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Background: Actinic damage is responsible for the development of multiple, recurrent non-melanoma skin cancers (NMSCs), including actinic keratoses (AKs). Photodynamic therapy (PDT) and imiquimod cream (IMIQ) 5% are recommended as field-directed treatment options. Objectives: To compare efficacy and safety of methyl aminolevulinate (MAL)-PDT vs. IMIQ 5% in the prevention of new NMSCs development patients with field changes. Methods: Patients with field cancerization of the face or scalp were randomized to receive MAL-PDT on one side, and IMIQ 5% on the mirror field. The primary endpoint was the number of new lesions on the treated fields during a 12-month follow-up period. Secondary assessments included adverse events and patient preference. Results: Forty-four patients completed the study. MAL-PDT and IMIQ did not differ concerning the primary endpoint, as there was no statistically significant difference in terms of development of new NMSCs at any point of follow-up. Both treatment regimens were safe and well tolerated. Patients' preference based on the procedure, response rates and future choice favoured MAL-PDT. Conclusions: MAL-PDT and IMIQ 5% are safe and well-tolerated treatments that equally prevent development of new AKs in patients suffering from field changes. MAL-PDT treatment appears to be superior in terms of patients' preference.

AB - Background: Actinic damage is responsible for the development of multiple, recurrent non-melanoma skin cancers (NMSCs), including actinic keratoses (AKs). Photodynamic therapy (PDT) and imiquimod cream (IMIQ) 5% are recommended as field-directed treatment options. Objectives: To compare efficacy and safety of methyl aminolevulinate (MAL)-PDT vs. IMIQ 5% in the prevention of new NMSCs development patients with field changes. Methods: Patients with field cancerization of the face or scalp were randomized to receive MAL-PDT on one side, and IMIQ 5% on the mirror field. The primary endpoint was the number of new lesions on the treated fields during a 12-month follow-up period. Secondary assessments included adverse events and patient preference. Results: Forty-four patients completed the study. MAL-PDT and IMIQ did not differ concerning the primary endpoint, as there was no statistically significant difference in terms of development of new NMSCs at any point of follow-up. Both treatment regimens were safe and well tolerated. Patients' preference based on the procedure, response rates and future choice favoured MAL-PDT. Conclusions: MAL-PDT and IMIQ 5% are safe and well-tolerated treatments that equally prevent development of new AKs in patients suffering from field changes. MAL-PDT treatment appears to be superior in terms of patients' preference.

UR - http://www.scopus.com/inward/record.url?scp=84921559033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921559033&partnerID=8YFLogxK

U2 - 10.1111/jdv.12538

DO - 10.1111/jdv.12538

M3 - Article

C2 - 24754529

AN - SCOPUS:84921559033

VL - 29

SP - 325

EP - 329

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 2

ER -